guest ::
| Home > Publications database > Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models. > print |
| Home > Publications database > Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models. > print |
| 001 | 302883 | ||
| 005 | 20250720021527.0 | ||
| 024 | 7 | _ | |a 10.1038/s44355-025-00018-y |2 doi |
| 024 | 7 | _ | |a pmid:40626281 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC7617876 |2 pmc |
| 024 | 7 | _ | |a altmetric:176218223 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01423 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Desert, Romain |b 0 |
| 245 | _ | _ | |a Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models. |
| 260 | _ | _ | |a Seoul |c 2025 |b Ed. Office of Gut and Liver |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1752751197_14020 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Hepatocellular carcinoma (HCC), the third cause of cancer-related deaths worldwide, continues to present significant therapeutic challenges. Despite significant therapeutic advancement in the last decade, the efficacy of systemic treatments for patients with advanced HCC remains unsatisfactory. While the clinical introduction of immune checkpoint inhibitors has improved response rates and overall survival, their clinical success remains still limited. Here we provide a comprehensive review of current and emerging strategies aimed at enhancing the efficacy of immunotherapy for the treatment of HCC. Both clinical studies conducted in patients as well as studies in preclinical models have markedly advanced our understanding of resistance as well as uncovered novel approaches to overcome resistance. Recent progress is paving the way for improved efficacy and safety of novel approaches that will improve the dismal prognosis of patients with advanced HCC. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Immune Checkpoint Inhibitors |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Carcinoma, Hepatocellular: therapy |2 MeSH |
| 650 | _ | 2 | |a Carcinoma, Hepatocellular: immunology |2 MeSH |
| 650 | _ | 2 | |a Liver Neoplasms: therapy |2 MeSH |
| 650 | _ | 2 | |a Liver Neoplasms: immunology |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy: methods |2 MeSH |
| 650 | _ | 2 | |a Immune Checkpoint Inhibitors: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Disease Models, Animal |2 MeSH |
| 700 | 1 | _ | |a Gianonne, Fabio |b 1 |
| 700 | 1 | _ | |a Saviano, Antonio |b 2 |
| 700 | 1 | _ | |a Hoshida, Yujin |b 3 |
| 700 | 1 | _ | |a Heikenwälder, Mathias |0 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5 |b 4 |u dkfz |
| 700 | 1 | _ | |a Nahon, Pierre |b 5 |
| 700 | 1 | _ | |a Baumert, Thomas F |b 6 |
| 773 | _ | _ | |a 10.1038/s44355-025-00018-y |g Vol. 2, no. 1, p. 8 |0 PERI:(DE-600)2536214-8 |n 1 |p 8 |t Gut and liver |v 2 |y 2025 |x 1976-2283 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:302883 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b GUT LIVER : 2022 |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-10-13T15:29:10Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-10-13T15:29:10Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : single blind peer review |d 2023-10-13T15:29:10Z |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC (No Version) |0 LIC:(DE-HGF)CCBYNCNV |2 V:(DE-HGF) |b DOAJ |d 2023-10-13T15:29:10Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-18 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-18 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-18 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-18 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-18 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-18 |
| 920 | 1 | _ | |0 I:(DE-He78)D440-20160331 |k D440 |l Chronische Entzündung und Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D440-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|